BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

14848

532878

ALPA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ALPA LABORATORIES LTD performance

Today’s low

Today’s high

₹ 102.00 ₹ 107.50
₹ 103.26

52 week low

52 week high

₹ 69.90 ₹ 144.50
₹ 103.26

Open Price

₹ 106.30

Prev. Close

₹ 105.32

Volume (Shares)

22161.00

Total traded value

₹ 22.88

Upper Circuit

₹ 126.38

Lower Circuit

₹ 84.25

info

ALPA LABORATORIES LTD Share Price Update

As of the latest trading session, ALPA LABORATORIES LTD share price is currently at ₹ 103.26, which is down by ₹ -2.05 from its previous closing. Today, the stock has fluctuated between ₹ 102.00 and ₹ 107.50. Over the past year, ALPA LABORATORIES LTD has achieved a return of 8.46 %. In the last month alone, the return has been -3.15 %. Read More...

ALPA LABORATORIES LTD fundamentals


  • Market cap (Cr)

    217.26

  • P/E Ratio (TTM)

    8.57

  • Beta

    1.16

  • Book Value / share

    83.05

  • Return on equity

    10.93%

  • EPS (TTM)

    11.96

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    8.89

info icon alternate text
  • Market cap (Cr)

    215.80

  • P/E Ratio (TTM)

    8.57

  • Beta

    1.02

  • Book Value / share

    83.05

  • Return on equity

    10.93%

  • EPS (TTM)

    11.96

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    8.89

info icon alternate text

ALPA LABORATORIES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 26.15
Operating Expense 26.06
Net Profit 8.89
Net Profit Margin (%) 33.99
Earnings Per Share (EPS) 4.24
EBITDA 9.54
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 24.94
Operating Expense 22.25
Net Profit 7.63
Net Profit Margin (%) 30.59
Earnings Per Share (EPS) 3.63
EBITDA 10.18
Effective Tax Rate (%) 20.43
Particulars JUN 2024 (Values in Cr)
Revenue 21.44
Operating Expense 21.49
Net Profit 5.12
Net Profit Margin (%) 23.88
Earnings Per Share (EPS) 2.44
EBITDA 5.71
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 23.61
Operating Expense 20.91
Net Profit 3.55
Net Profit Margin (%) 15.03
Earnings Per Share (EPS) 1.70
EBITDA 7.48
Effective Tax Rate (%) 46.69
Particulars DEC 2023 (Values in Cr)
Revenue 27.31
Operating Expense 25.54
Net Profit 4.53
Net Profit Margin (%) 16.58
Earnings Per Share (EPS) 2.15
EBITDA 6.01
Effective Tax Rate (%) 14.84
Particulars MAR 2024 (Values in Cr)
Revenue 108.74
Operating Expense 102.94
Net Profit 16.78
Net Profit Margin (%) 15.43
Earnings Per Share (EPS) 8.01
EBITDA 23.01
Effective Tax Rate (%) 18.86
Particulars MAR 2023 (Values in Cr)
Revenue 92.44
Operating Expense 86.42
Net Profit 12.63
Net Profit Margin (%) 13.66
Earnings Per Share (EPS) 5.90
EBITDA 17.47
Effective Tax Rate (%) 20.77
Particulars MAR 2022 (Values in Cr)
Revenue 112.27
Operating Expense 103.47
Net Profit 14.13
Net Profit Margin (%) 12.58
Earnings Per Share (EPS) 6.71
EBITDA 21.47
Effective Tax Rate (%) 27.83
Particulars MAR 2021 (Values in Cr)
Revenue 97.55
Operating Expense 91.16
Net Profit 7.26
Net Profit Margin (%) 7.44
Earnings Per Share (EPS) 3.46
EBITDA 12.12
Effective Tax Rate (%) 32.71
Particulars MAR 2020 (Values in Cr)
Revenue 85.97
Operating Expense 83.86
Net Profit 4.08
Net Profit Margin (%) 4.74
Earnings Per Share (EPS) 1.95
EBITDA 6.42
Effective Tax Rate (%) 19.68
Particulars MAR 2024 (Values in Cr)
Book Value / Share 72.20
ROE % 11.71
ROCE % 14.32
Total Debt to Total Equity 0.03
EBITDA Margin 21.15
Particulars MAR 2023 (Values in Cr)
Book Value / Share 63.96
ROE % 9.82
ROCE % 12.18
Total Debt to Total Equity 0.03
EBITDA Margin 18.76
Particulars MAR 2022 (Values in Cr)
Book Value / Share 57.86
ROE % 6.73
ROCE % 9.30
Total Debt to Total Equity 0.03
EBITDA Margin 11.23
Particulars MAR 2021 (Values in Cr)
Book Value / Share 51.16
ROE % 4.99
ROCE % 7.44
Total Debt to Total Equity 0.00
EBITDA Margin 9.22
Particulars MAR 2020 (Values in Cr)
Book Value / Share 47.70
ROE % 2.66
ROCE % 5.35
Total Debt to Total Equity 0.01
EBITDA Margin 9.94
Particulars MAR 2024 (Values in Cr)
Book Value / Share 76.98
ROE % 10.93
ROCE % 13.38
Total Debt to Total Equity 0.03
EBITDA Margin 21.17
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.97
ROE % 9.12
ROCE % 11.33
Total Debt to Total Equity 0.03
EBITDA Margin 18.80
Particulars MAR 2022 (Values in Cr)
Book Value / Share 62.56
ROE % 6.22
ROCE % 8.60
Total Debt to Total Equity 0.02
EBITDA Margin 11.25
Particulars MAR 2021 (Values in Cr)
Book Value / Share 55.85
ROE % 4.53
ROCE % 6.77
Total Debt to Total Equity 0.00
EBITDA Margin 9.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 52.39
ROE % 4.98
ROCE % 6.75
Total Debt to Total Equity 0.01
EBITDA Margin 9.90
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.71
Total Assets 182.37
Total Liabilities 182.37
Total Equity 151.90
Share Outstanding 21040600
Price to Book Ratio 1.08
Return on Assets (%) 9.19
Return on Capital (%) 10.68
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.81
Total Assets 167.26
Total Liabilities 167.26
Total Equity 134.57
Share Outstanding 21040600
Price to Book Ratio 0.78
Return on Assets (%) 7.52
Return on Capital (%) 9.19
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.57
Total Assets 155.23
Total Liabilities 155.23
Total Equity 121.73
Share Outstanding 21040600
Price to Book Ratio 1.11
Return on Assets (%) 9.07
Return on Capital (%) 11.05
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.51
Total Assets 140.36
Total Liabilities 140.36
Total Equity 107.64
Share Outstanding 21040600
Price to Book Ratio 0.65
Return on Assets (%) 5.16
Return on Capital (%) 6.72
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 6.16
Total Assets 121.35
Total Liabilities 121.35
Total Equity 100.37
Share Outstanding 21040600
Price to Book Ratio 0.27
Return on Assets (%) 1.52
Return on Capital (%) 1.84
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.25
Total Assets 192.42
Total Liabilities 192.42
Total Equity 161.97
Share Outstanding 21040600
Price to Book Ratio 1.08
Return on Assets (%) 8.71
Return on Capital (%) 10.03
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.74
Total Assets 178.08
Total Liabilities 178.08
Total Equity 145.11
Share Outstanding 21040600
Price to Book Ratio 0.78
Return on Assets (%) 7.08
Return on Capital (%) 8.55
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.31
Total Assets 165.13
Total Liabilities 165.13
Total Equity 131.63
Share Outstanding 21040600
Price to Book Ratio 1.11
Return on Assets (%) 8.55
Return on Capital (%) 10.27
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.23
Total Assets 150.23
Total Liabilities 150.23
Total Equity 117.52
Share Outstanding 21040600
Price to Book Ratio 0.65
Return on Assets (%) 4.83
Return on Capital (%) 6.17
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.91
Total Assets 131.20
Total Liabilities 131.20
Total Equity 110.23
Share Outstanding 21040600
Price to Book Ratio 0.27
Return on Assets (%) 3.10
Return on Capital (%) 3.69
Particulars MAR 2024 (Values in Cr)
Net Income 20.76
Cash from Operations 7.28
Cash from Investing -13.33
Cash from Financing 2.58
Net change in Cash -7.10
Free Cash Flow 13.67
Particulars MAR 2023 (Values in Cr)
Net Income 15.68
Cash from Operations 12.49
Cash from Investing 2.12
Cash from Financing -3.79
Net change in Cash 7.23
Free Cash Flow 13.62
Particulars MAR 2022 (Values in Cr)
Net Income 19.56
Cash from Operations 13.05
Cash from Investing -15.60
Cash from Financing 5.44
Net change in Cash -0.22
Free Cash Flow 15.24
Particulars MAR 2021 (Values in Cr)
Net Income 10.79
Cash from Operations 1.15
Cash from Investing 5.86
Cash from Financing 0.19
Net change in Cash 4.34
Free Cash Flow 4.37
Particulars MAR 2020 (Values in Cr)
Net Income 2.90
Cash from Operations 18.94
Cash from Investing -11.16
Cash from Financing -1.34
Net change in Cash 5.27
Free Cash Flow 21.48
Particulars MAR 2024 (Values in Cr)
Net Income 20.75
Cash from Operations 7.33
Cash from Investing -12.44
Cash from Financing 2.26
Net change in Cash -6.48
Free Cash Flow 13.71
Particulars MAR 2023 (Values in Cr)
Net Income 15.72
Cash from Operations 13.79
Cash from Investing 1.16
Cash from Financing -3.47
Net change in Cash 7.88
Free Cash Flow 14.92
Particulars MAR 2022 (Values in Cr)
Net Income 19.57
Cash from Operations 5.77
Cash from Investing -15.60
Cash from Financing 5.41
Net change in Cash -7.99
Free Cash Flow 7.96
Particulars MAR 2021 (Values in Cr)
Net Income 10.79
Cash from Operations 1.39
Cash from Investing 5.81
Cash from Financing -0.02
Net change in Cash 4.32
Free Cash Flow 4.61
Particulars MAR 2020 (Values in Cr)
Net Income 5.07
Cash from Operations 18.76
Cash from Investing -11.27
Cash from Financing -1.35
Net change in Cash 5.03
Free Cash Flow 21.30
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

ALPA LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
103.26 -1.95 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 106.10
  • 26 Days 107.70
  • 10 Days 107.20
  • 50 Days 108.70
  • 12 Days 107.40
  • 100 Days 110.20
  • 20 Days 107.60
  • 200 Days 108.10
105.87 PIVOT

First Support

103.86

First Resistance

107.34

Second Support

102.39

Second Resistance

109.35

Third Support

100.38

Third Resistance

110.82

RSI

43.04

ADX

16.17

MACD

-0.30

Williams % R

-75.77

Commodity Channel Index (CCI)

-82.00

Date

2025-04-30

Week

23130.00

Same Day

14188.00

Month

22014.00

1 Year

1.16

3 Year

0.99

Over 1 Month

-3.15%

down

Over 1 Year

8.46%

down

Over 3 Months

-10.54%

down

Over 3 Years

8.99%

down

Over 6 Months

-7.09%

down

Over 5 Years

38.10%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ALPA LABORATORIES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
42.3%
Promoter Holdings
57.29%
FII
0.39%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Paresh Chawla 3686450.0 (17.52%) Shareholding of Promoter and Promoter Group
Mahendra Singh Chawla 2906760.0 (13.82%) Shareholding of Promoter and Promoter Group
Pravin Shah 1210580.0 (5.75%) Shareholding of Promoter and Promoter Group
Bakulesh Shah 1026600.0 (4.88%) Shareholding of Promoter and Promoter Group
Shitul Shah 925200.0 (4.4%) Shareholding of Promoter and Promoter Group
Rima Shah 775200.0 (3.68%) Shareholding of Promoter and Promoter Group
Asha Chawla 616700.0 (2.93%) Shareholding of Promoter and Promoter Group
Rupal Shah 558780.0 (2.66%) Shareholding of Promoter and Promoter Group
Soni Chawla 326800.0 (1.55%) Shareholding of Promoter and Promoter Group
Bakulesh Chandulal Shah Huf 21940.0 (0.1%) Shareholding of Promoter and Promoter Group
Saraswati Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mitin Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Meeta Sethi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pooja Chawla 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

ALPA LABORATORIES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ALPA LABORATORIES LTD Share Price

M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company in the name of Alpa Laboratories Private Limited on March 18, 1988 for manufacture of pharmaceutical formulations. In 1998, the Company was converted into a Public Limited Company with effect from September 3, 1998 with the name of 'Alpa Laboratories Limited'. The facility has dedicated manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels.

In 1997, the company has initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh. The unit commenced commercial production in the year 1999 of all types of formulations viz. Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams.

The company has manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark 'Alpa' which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company. The company has also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands) located both in India and abroad in countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Srilanka etc. Further, the company has also undertaken contract manufacturing of a large variety of pharmaceuticals.

The company has manufacture various dosage forms which include injectables (vials / ampoules both liquid and dry), tablets, capsules, eye / ear drops, ointment and creams and dry syrups. The company has an established product-marketing network covering both metro and mini metro cities, which enable company to reach the existing and potential customers through the network of distributors and dealers spread across the country. For the purpose of marketing the various products, the company's business has been categorized as Branded Generic Division, Veterinary Division, Exports Division and Contract Manufacturing Division.

The Company came out with an Initial Public Offer in July 2007 and got listed on The n The Bombay Stock Exchange and The National Stock Exchange on 06lh August, 2008.

The Unit-II oral solid dosage manufacturing facility focusing on containment products such as oral hormonal and other oral hi-potency formulations was made operational at Pithampur Industrial Area in 2012.

The Company in FY 2014-15, acquired 100% of the shares of Norfolk Mercantile Private Limited making it a wholly owned subsidiary.

Parent organization Indian Private
NSE symbol ALPA
Founded 1988
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Alpa Laboratories Ltd?

Answer Field

The share price of Alpa Laboratories Ltd for NSE is ₹ 103.26 and for BSE is ₹ 102.55.

What is the Market Cap of Alpa Laboratories Ltd?

Answer Field

The market cap of Alpa Laboratories Ltd for NSE is ₹ 2,17.26 Cr. and for BSE is ₹ 2,15.77 Cr. as of now.

What is the 52 Week High and Low of Alpa Laboratories Ltd?

Answer Field

The 52 Week High and Low of Alpa Laboratories Ltd for NSE is ₹ 144.50 and ₹ 69.90 and for BSE is ₹ 144.60 and ₹ 71.00.

How to Buy Alpa Laboratories Ltd share?

Answer Field

You can trade in Alpa Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Alpa Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 8.46%.

What is the Current Share Price of Alpa Laboratories Ltd?

Answer Field

Alpa Laboratories Ltd share price is for NSE ₹ 103.26 & for BSE ₹ 102.55 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Alpa Laboratories Ltd Share?

Answer Field

The market cap of Alpa Laboratories Ltd for NSE ₹ 2,17.26 & for BSE ₹ 2,15.77 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Alpa Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Alpa Laboratories Ltd share is 8.57.

What is the PB ratio of Alpa Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Alpa Laboratories Ltd share is 83.05.

How to Buy Alpa Laboratories Ltd Share?

Answer Field

You can trade in Alpa Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Alpa Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Alpa Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Alpa Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|